Study S000434

BARI-STEP:A Double-blinded, Randomised, Placebo-controlled Trial of Semaglutide 2.4 mg in Patients With Poor Weight-loss Following Bariatric Surgery.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT05073835
Acronym: BARI-STEP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 70
Start: 2022-11-01
Primary completion: 2025-03
Lead sponsor: University College, London
Conditions: Obesity; Diabetes; Metabolic Syndrome
Interventions: DRUG:Semaglutide 3 mg; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Weight loss [68 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014003	Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. Stanley C, Nature medicine	2026	Randomized trial	PMID 42174253 DOI	cites ClinicalTrials.gov:NCT05073835; registry reference DERIVED:42174253